Neuronal acetylcholine receptor subunit alpha-7


  • Accession: P36544
  • Swissprot: ACHA7_HUMAN
  • Organism: Homo sapiens
  • Gene: CHRNA7
  • Target class: Ion channel

Drug Relations:

A neurotransmitter found at neuromuscular junctions, autonomic ganglia, parasympathetic effector junctions, a subset of sympathetic effector junctions, and at many sites in the central nervous system. Miochol-E (acetylcholine chloride intraocular solution) is used to obtain miosis of the iris in seconds after delivery of the lens in cataract surgery, in penetrating keratoplasty, iridectomy and other anterior segment surgery where rapid miosis may be required. Bioactivity details MOA
A non-depolarizing skeletal muscle relaxant similar to TUBOCURARINE. It is used as an anesthesia adjuvant, for endotracheal intubation and to produce muscle relaxation in general anesthesia during surgical procedures. Bioactivity details MOA
A non-depolarizing neuromuscular blocking agent with short duration of action. Its lack of significant cardiovascular effects and its lack of dependence on good kidney function for elimination provide clinical advantage over alternate non-depolarizing neuromuscular blocking agents. Bioactivity details MOA
A propiophenone-derived antidepressant and antismoking agent that inhibits the uptake of DOPAMINE. Bioactivity details MOA
A slowly hydrolyzed CHOLINERGIC AGONIST that acts at both MUSCARINIC RECEPTORS and NICOTINIC RECEPTORS. Bioactivity details MOA
RN given refers to (R)-isomer; structure Bioactivity details MOA
A mixture of mostly avermectin H2B1a (RN 71827-03-7) with some avermectin H2B1b (RN 70209-81-3), which are macrolides from STREPTOMYCES avermitilis. It binds glutamate-gated chloride channel to cause increased permeability and hyperpolarization of nerve and muscle cells. It also interacts with other CHLORIDE CHANNELS. It is a broad spectrum antiparasitic that is active against microfilariae of ONCHOCERCA VOLVULUS but not the adult form. In vitro data suggest evidence of activity against SARS-CoV-2, but to date available data are insufficient to recommend either for or against the use of ivermectin for the treatment of COVID-19. FDA issued a warning concerning possi-ble inappropriate use of ivermectin products intended for animals as an attempt to self-medicate for the treat-ment of COVID-19. Bioactivity details MOA
drug combination containing chamomile and bisabolol; used to treat dermatitis Bioactivity details MOA
A nicotinic antagonist that is well absorbed from the gastrointestinal tract and crosses the blood-brain barrier. Mecamylamine has been used as a ganglionic blocker in treating hypertension, but, like most ganglionic blockers, is more often used now as a research tool. Bioactivity details MOA
Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of NALOXONE. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence. Bioactivity details MOA
Devices or delivery systems used to aid in ending a TOBACCO habit. Bioactivity details MOA
A nicotinic antagonist that has been used as a ganglionic blocker in hypertension, as an adjunct to anesthesia, and to induce hypotension during surgery. Bioactivity details MOA
An indole derivative and 5-HT3 RECEPTOR antagonist that is used for the prevention of nausea and vomiting. Bioactivity details MOA
A neuromuscular blocker and active ingredient in CURARE; plant based alkaloid of Menispermaceae. Bioactivity details MOA
A benzazepine derivative that functions as an ALPHA4-BETA2 NICOTINIC RECEPTOR partial agonist. It is used for SMOKING CESSATION. Bioactivity details MOA